ReviewFrontiers in medicine2023
Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report.Frontiers in medicine · 2026Article
- Dupilumab for Drug-Induced Bullous Pemphigoid: A Case Series and Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study.Scientific reports · 2025Article
- Immunophenotypic and Transcriptomic Analysis of Peripheral Blood Mononuclear Cells in Bullous Pemphigoid.Annals of dermatology · 2025Article
- Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.Current treatment options in oncology · 2025Review
- A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab.Skin health and disease · 2025Article
- Case Report: Dupilumab in difficult-to-treat bullous pemphigoid at the University Hospital Schleswig-Holstein, Campus Kiel.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases and mainly affects an elderly population with multi-morbidity. Due to the frailty of many BP patients, existing treatment options are limited. The blisters associated with BP result from IgG and IgE autoantibodies binding to the central components of hemidesmosome, BP180, and BP230, stimulating a destructive inflammatory process. The known characteristic features of BP, such as intense pruritus, urticarial prodrome, peripheral eosinophilia, elevated IgE, as well as recent expanding evidence from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.